Comparative Pharmacology
Head-to-head clinical analysis: REDEMPLO versus TURQOZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REDEMPLO versus TURQOZ.
REDEMPLO vs TURQOZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
REDEMPLO is a synthetic tricyclic analog that acts as a selective serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It binds to the presynaptic transporters for serotonin (SERT), norepinephrine (NET), and dopamine (DAT), inhibiting their reuptake and increasing synaptic concentrations of these monoamines. Additionally, it has weak antagonistic properties at the 5-HT2A and alpha-2 adrenergic receptors, contributing to its antidepressant and anxiolytic effects.
TURQOZ is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the synaptic cleft, leading to increased serotonin levels.
100 mg orally once daily, with or without food.
400 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours) and end-stage renal disease (up to 40 hours).
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours) requiring dose adjustment
Primarily hepatic metabolism with 70% renal excretion of metabolites and 30% fecal elimination; less than 5% excreted unchanged in urine.
Primarily renal (80% unchanged) with 10% fecal, 5% biliary, 5% other
Category C
Category C
Unknown
Unknown